Plans to employ around 100 people
Baxalta, a new biopharmaceutical company formed following its separation from Baxter International, of Deerfield, Illinois, US, has opened a UK headquarters in Staines, Middlesex, with plans to employ around 100 people.
Launched on 1 July, the US$6bn global biopharmaceutical company is focused on the development of therapies for orphan diseases and under-served conditions in haematology, immunology and oncology.
Baxalta, which has a strong foothold in haematology and immunology, aims to expand its oncology portfolio for patients with limited treatment options. The company plans to launch 20 new products across the globe by 2020.
The Baxalta Global Innovation and R&D Centre is located in Cambridge, Massachusetts.
Headquartered in Northern Illinois, Baxalta employs 16,000 people worldwide.
